title: Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience.
abstract: Sorafenib is the standard treatment of patients with advanced hepatocellular carcinoma (HCC), with demonstrated outcome benefits in randomized clinical trials. We present a single-center experience with sorafenib with the aim to establish its efficacy and safety in daily clinical practice. A total of 62 patients were treated with sorafenib 400 mg/12 h until disease progression or unacceptable toxicity. Response rates, incidence of adverse events, actuarial disease-free survival, and overall survival (OS) were estimated. Univariate and multivariate analyses of prognostic factors for survival were also performed. Median treatment duration was 92 days. A 43% disease control rate was achieved (partial response, 15% and disease stabilization, 28%). After a median follow-up of 24.1 months, the median progression-free survival and OS for the overall population were 5.8 and 6.7 months, respectively, with survival rates of 27% at 1 year and 17 % at 2 years. The most common grade 3-4 adverse events were fatigue (19%), hand-foot syndrome (8%), hypertension (5%), and diarrhea (3%). The univariate analysis showed that patient performance status (PS), use of previous treatments, and albumin >3.5 g/dL were significant prognostic factors for survival. In the multivariate study, only PS, alcoholic etiology and albumin >3.5 g/dL remained as independent predictors of survival. Sorafenib is a safe and moderately effective drug in HCC, although patients must be properly selected before starting therapy. Baseline PS, Barcelona Clinic Liver Cancer staging, and liver function should be taken into account as prognostic factors. Results in daily practice are somewhat inferior than observed in clinical trials.
authors.affiliation: Department of Medical Oncology, University Hospital La fe, Valencia, Spain.
authors.forename: Esteban Rodrigo
authors.initials: ER
authors.lastname: Imedio
authors.forename: Roberto Díaz
authors.initials: RD
authors.lastname: Beveridge
authors.forename: Jorge Aparicio
authors.initials: JA
authors.lastname: Urtasun
authors.forename: Gema Bruixola
authors.initials: GB
authors.lastname: Campos
authors.forename: David Lorente
authors.initials: DL
authors.lastname: Estellés
authors.forename: María Fonfría
authors.initials: MF
authors.lastname: Esparcia
authors.forename: Javier Caballero
authors.initials: JC
authors.lastname: Daroqui
authors.forename: Ángel Segura
authors.initials: ÁS
authors.lastname: Huerta
authors.forename: Alejandra Giménez
authors.initials: AG
authors.lastname: Ortiz
authors.forename: Joaquin Montalar
authors.initials: JM
authors.lastname: Salcedo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D011379:Prognosis; D012189:Retrospective Studies; D012449:Safety; D000077157:Sorafenib; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib
references.citation: Aliment Pharmacol Ther. 2010 Feb 15;31(4):461-76
references.pmid: 19925500
references.citation: Semin Liver Dis. 1999;19(3):329-38
references.pmid: 10518312
references.citation: J Clin Oncol. 2010 May 10;28(14):2437-44
references.pmid: 20368541
references.citation: Gastroenterology. 2010 May;138(5):1747-54
references.pmid: 20114048
references.citation: Hepatology. 1999 Jan;29(1):62-7
references.pmid: 9862851
references.citation: J Clin Oncol. 2006 Sep 10;24(26):4293-300
references.pmid: 16908937
references.citation: Bull Cancer. 2000 Dec;87(12):881-6
references.pmid: 11174117
references.citation: Hepatology. 2005 Nov;42(5):1208-36
references.pmid: 16250051
references.citation: Nat Rev Clin Oncol. 2009 Sep;6(9):505-6
references.pmid: 19707242
references.citation: Lancet. 1981 Nov 21;2(8256):1129-33
references.pmid: 6118576
references.citation: N Engl J Med. 2008 Jul 24;359(4):378-90
references.pmid: 18650514
references.citation: Lancet Oncol. 2009 Jan;10(1):25-34
references.pmid: 19095497
references.citation: Eur J Gastroenterol Hepatol. 2010 Apr;22(4):391-8
references.pmid: 19940784
references.citation: Semin Liver Dis. 2010 Feb;30(1):61-74
references.pmid: 20175034
references.citation: Clin Transl Oncol. 2011 Aug;13(8):536-44
references.pmid: 21821487
references.citation: J Hepatol. 2009 Jan;50(1):80-8
references.pmid: 18977053
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Clin Transl Oncol. 2013 Feb;15(2):146-53
references.pmid: 22875650
references.citation: Aliment Pharmacol Ther. 2011 Nov;34(10):1193-201
references.pmid: 21958438